Paid Clinical Trials Vancouver

Discover 691 paid clinical trials in Vancouver, British Columbia. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.

Filter

Filter results

Results: 691

Canadian Network for Autoimmune Liver DiseaseCanadian Network for Autoimmune Liver Disease

Recruiting

Sponsor:

University Health Network, Toronto

Location:

Vancouver, Calgary, Edmonton, Saskatoonshow 9 more

Code:

NCT03569826

Conditions

Primary Bilary Cirrhosis (PBC)

Autoimmune Hepatitis

Overlap Syndrome

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Observational; no intervention

LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have CirrhosisLIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

Recruiting

PHASE3

Sponsor:

Boehringer Ingelheim

Location:

Vancouver, Seattle WA, Calgary, Draper UTshow 82 more

Code:

NCT06632457

Conditions

Metabolic Dysfunction Associated Steatohepatitis

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Survodutide

Placebo matching survodutide

A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology ProductsA Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products

Recruiting

Sponsor:

Hoffmann-La Roche

Location:

New Westminster, Spokane WA, Sacramento CA, Salt Lake City UTshow 25 more

Code:

NCT05476926

Conditions

Neovascular Age-related Macular Degeneration

Diabetic Macular Edema

Retinal Vein Occlusion

Branch Retinal Vein Occlusion

Central Retinal Vein Occlusion

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Faricimab

Port Delivery System with Ranibizumab

Comparing Retreatment of 177Lu-DOTATATE PRRT Versus Everolimus in Patients With Metastatic Unresectable Midgut Neuroendocrine Tumors, NET RETREAT TrialComparing Retreatment of 177Lu-DOTATATE PRRT Versus Everolimus in Patients With Metastatic Unresectable Midgut Neuroendocrine Tumors, NET RETREAT Trial

Recruiting

PHASE2

Sponsor:

National Cancer Institute (NCI)

Location:

Vancouver, Salt Lake City UT, Aurora CO, Winnipegshow 22 more

Code:

NCT05773274

Conditions

Metastatic Midgut Neuroendocrine Tumor

Metastatic Midgut Neuroendocrine Tumor G1

Metastatic Midgut Neuroendocrine Tumor G2

Unresectable Midgut Neuroendocrine Tumor

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Biospecimen Collection

Computed Tomography

Everolimus

Lutetium Lu 177 Dotatate

Quality-of-Life Assessment

Prostate Active Surveillance StudyProstate Active Surveillance Study

Recruiting

Sponsor:

University of Washington

Location:

Vancouver, Seattle WA, San Francisco CA, Stanford CAshow 5 more

Code:

NCT00756665

Conditions

Prostatic Neoplasms

Eligibility Criteria

Sex: Male

Age: 21+

Healthy Volunteers: Not accepted

Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal AdenocarcinomaPaclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal Adenocarcinoma

Recruiting

PHASE2

Sponsor:

Canadian Cancer Trials Group

Location:

Vancouver, Calgary, Saskatoon, Reginashow 10 more

Code:

NCT06043427

Conditions

Gastroesophageal Adenocarcinoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Paclitaxel

Ramucirumab

Zanidatamab

Real-world Clinical Outcomes of the MITRIS RESILIA Mitral ValveReal-world Clinical Outcomes of the MITRIS RESILIA Mitral Valve

Recruiting

Sponsor:

Edwards Lifesciences

Location:

Vancouver, Salt Lake City UT, Palo Alto CA, Los Angeles CAshow 19 more

Code:

NCT05526560

Conditions

Mitral Stenosis

Mitral Valve Insufficiency

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

MITRIS RESILIA Mitral Valve, Model 11400M

A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate CancerA Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer

Recruiting

PHASE1

Sponsor:

Genentech, Inc.

Location:

Vancouver, Scottsdale AZ, Chicago IL, Nashville TNshow 3 more

Code:

NCT05800665

Conditions

Advanced Prostate Cancer

Metastatic Prostate Cancer

Eligibility Criteria

Sex: Male

Age: 18+

Healthy Volunteers: Not accepted

Interventions

RO7656594

Fixed Duration vs Continuous Daratumumab in Transplant Ineligible Older Adults With Newly Diagnosed Multiple MyelomaFixed Duration vs Continuous Daratumumab in Transplant Ineligible Older Adults With Newly Diagnosed Multiple Myeloma

Recruiting

PHASE3

Sponsor:

Canadian Cancer Trials Group

Location:

Vancouver, Kelowna, Saskatoon, Reginashow 16 more

Code:

NCT06182774

Conditions

Multiple Myeloma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Daratumumab

Lenalidomide

Dexamethasone

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

Recruiting

PHASE3

Sponsor:

Merck Sharp & Dohme LLC

Location:

Vancouver, Walnut Creek CA, Los Alamitos CA, Winnipegshow 29 more

Code:

NCT06393374

Conditions

Triple-Negative Breast Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Pembrolizumab

Sacituzumab tirumotecan

Capecitabine